Additionally, to correlate TARBP2 expression with the survival of HCC patients, we mined the PRECOG database to collect survival rates from groups of 50 (Fig. 1C; HR = 0.26; 95% CI: 0.07–0.95, P = 2.37e‐02) and 91 patients (Fig. 1D; HR = 0.52; 95% CI: 0.29–0.96, P = 3.27e‐02) with liver cancer for Kaplan–Meier survival analysis (Fernandez‐Ricaud et al., 2016). Here, TARBP2 is linked to hepatocellular carcinoma.